590 related articles for article (PubMed ID: 28732839)
1. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
2. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
3. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
4. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
5. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
Esquinas C; Serreri S; Barrecheguren M; Rodriguez E; Nuñez A; Casas-Maldonado F; Blanco I; Pirina P; Lara B; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1001-1007. PubMed ID: 29615836
[TBL] [Abstract][Full Text] [Related]
6. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
7. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
Piitulainen E; Mostafavi B; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.
Stoller JK; Aboussouan LS; Kanner RE; Wilson LA; Diaz P; Wise R;
Ann Am Thorac Soc; 2015 Dec; 12(12):1796-804. PubMed ID: 26653189
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.
Omachi TA; Eisner MD; Rames A; Markovtsova L; Blanc PD
Respir Res; 2011 Mar; 12(1):35. PubMed ID: 21429222
[TBL] [Abstract][Full Text] [Related]
10. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.
Vijayasaratha K; Stockley RA
Int J Chron Obstruct Pulmon Dis; 2012; 7():789-96. PubMed ID: 23226015
[TBL] [Abstract][Full Text] [Related]
11. Maximal mid-expiratory flow detects early lung disease in α
Stockley JA; Ismail AM; Hughes SM; Edgar R; Stockley RA; Sapey E
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356373
[TBL] [Abstract][Full Text] [Related]
12. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience.
Gauvain C; Mornex JF; Pison C; Cuvelier A; Balduyck M; Pujazon MC; Fournier M; AitIlalne B; Thabut G
COPD; 2015 May; 12 Suppl 1():46-51. PubMed ID: 25938292
[TBL] [Abstract][Full Text] [Related]
15. The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.
Banga A; Gildea T; Rajeswaran J; Rokadia H; Blackstone EH; Stoller JK
Am J Respir Crit Care Med; 2014 Aug; 190(3):274-81. PubMed ID: 25003824
[TBL] [Abstract][Full Text] [Related]
16. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
17. ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils.
Low EV; Hughes SM; Zaffarullah S; Kantas D; Stockley RA; Turner AM
Respiration; 2018; 95(2):114-121. PubMed ID: 29253843
[TBL] [Abstract][Full Text] [Related]
18. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary
Lessard E; Young HM; Bhalla A; Pike D; Sheikh K; McCormack DG; Ouriadov A; Parraga G
Acad Radiol; 2017 Nov; 24(11):1402-1411. PubMed ID: 28645458
[TBL] [Abstract][Full Text] [Related]
20. Patterns and characterization of COPD exacerbations using real-time data collection.
Ejiofor SI; Stolk J; Fernandez P; Stockley RA
Int J Chron Obstruct Pulmon Dis; 2017; 12():427-434. PubMed ID: 28182151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]